Guild Update – 1 March 16 : Hepatitis C – New Medicines PBS Listings Information
March 1, 2016
GUILD Members would be
aware that the Government has
approved listing of the following
medicines for hepatitis C from 1
March 2016:
• Daclatasvir (Daklinza®) 30 mg
tablet, 28 DPMQ $7,813.54
• Ledipasvir with sofosbuvir
(Harvoni®) 90 mg + 400 mg tablet,
28 DPMQ $22,213.54
• Sofosbuvir (Sovaldi®) 400 mg
tablet, 28 DPMQ $19,444.62
• Ribavirin (Ibavyr®) 400 mg
tablet, 28 DPMQ $160.95 and 600
mg tablet 28, $237.81
High Cost
Members should note the high
cost of some of these medicines.
Patients and prescribers should
be advised if these medicines are
ordered on demand rather than
stocked as a matter of course and
patients encouraged to lodge their
prescription in advance before
their current prescription runs
out to ensure there is no break in
treatment. Members should also
note that some wholesalers have
a “no return” policy of some of
these items and care should be
taken when ordering.
Further information on hepatitis C
listings is available at: http://www.
pbs.gov.au/info/news/2016/02/
info-about-new-hep-c-treatments
The above article was sent to subscribers in Pharmacy Daily's issue from 01 Mar 16To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 01 Mar 16